Autoimmune Encephalitis cost-effectiveness of therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
|
Autoimmune Encephalitis Microchapters |
|
Differentiating Autoimmune Encephalitis from Other Conditions |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune Encephalitis On the Web |
Overview
Autoimmune encephalitis can impose substantial hospital and long-term care costs. Published economic evidence includes resource-use studies and diagnostic-screening models, but these do not establish a universally most cost-effective immunotherapy.[1][2]
Cost-Effectiveness of Therapy
Interpretation of Economic Evidence
Autoimmune encephalitis cost-effectiveness assessments must compare both costs and health outcomes between strategies. A treatment with a lower purchase price is not necessarily better value if it leads to more complications, disability, or hospital care. Hospital-cost studies alone cannot establish an incremental cost-effectiveness ratio (ICER), which compares additional cost with additional health benefit. Quality-adjusted life-years (QALYs) combine survival and health-related quality of life.[2]
Hospital Resource Use
Autoimmune encephalitis resource use was evaluated in a 2026 German single-center retrospective cohort of 35 patients. Median direct hospital costs during the first year were €26,547 per patient. Patients admitted to an intensive care unit (ICU) had higher costs than those not admitted: €69,822 versus €20,234. Hospital duration, particularly ICU stay, was a major cost driver.[1]
Autoimmune encephalitis cost figures from this study reflect its setting, costing method, and case mix. They are not current treatment quotations, patient bills, or estimates for other countries. The study did not compare the cost per QALY of competing immunotherapies.[1]
Treatment Selection
Autoimmune encephalitis guidelines base therapy on diagnostic confidence, severity, antibody subtype, contraindications, and response. High-dose corticosteroids, intravenous immunoglobulin (IVIG), plasma exchange, and selected second-line treatments have different delivery and monitoring requirements. The Canadian consensus does not establish a formal economic ranking of these options.[3]
Autoimmune encephalitis treatment costs should therefore be considered together with clinical suitability, access, administration, adverse effects, and continuing care. Available evidence does not justify declaring rituximab, cyclophosphamide, IVIG, or plasma exchange the most cost-effective treatment for every patient.[3][1]
Timely Diagnosis and Coordinated Care
Autoimmune encephalitis care pathways may improve efficiency. A 2024 pediatric single-center study found shorter time to diagnostic evaluation and treatment after pathway implementation. It did not demonstrate a statistically significant reduction in hospital stay or provide a formal cost-effectiveness analysis.[4]
Autoimmune encephalitis guidelines recommend timely appropriate treatment for clinical benefit. Potential economic benefits should not be represented as proven savings without a comparative economic evaluation.[3][4]
Related Economic Evidence: Diagnostic Screening
Autoimmune encephalitis screening was assessed in a United States decision model comparing routine serum antibody screening with clinically targeted testing in first-episode psychosis. Over five years, estimated ICERs were US$99,330 per QALY from a societal perspective and US$147,460 per QALY from a healthcare-sector perspective. Model costs used 2015 United States dollars.[2]
Autoimmune encephalitis screening results depended strongly on assumptions, including immunotherapy effectiveness. This was a diagnostic-strategy model, not a head-to-head comparison of treatment regimens, and it does not independently establish a clinical recommendation for universal antibody screening.[2]
Evidence Limitations
Autoimmune encephalitis economic conclusions are limited by small cohorts, heterogeneous disease severity, local prices, different costing perspectives, and incomplete measurement of long-term disability and caregiver burden. Economic findings should not be transferred between healthcare systems without reassessment.[1][2]
Related Chapters
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Keller N, Bertram D, Hamer H, et al. Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study. Neurol Res Pract. 2026;8(1):26. doi:10.1186/s42466-026-00491-7. PMID:41998723.
- ↑ 2.0 2.1 2.2 2.3 2.4 Ross EL, Becker JE, Linnoila JJ, Soeteman DI. Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States. J Clin Psychiatry. 2020;82(1):19m13168. doi:10.4088/JCP.19m13168. PMID:33211912.
- ↑ 3.0 3.1 3.2 Hahn C, Budhram A, Alikhani K, et al. Canadian Consensus Guidelines for the Diagnosis and Treatment of Autoimmune Encephalitis in Adults. Can J Neurol Sci. 2024;51(6):734–754. doi:10.1017/cjn.2024.16. PMID:38312020.
- ↑ 4.0 4.1 Barter KM, Fuchs C, Graham TB, Pagano LM, Vater M. Anti-NMDAR Encephalitis Clinical Practice Guideline: Improving Time to Diagnosis, Treatment, and Hospital Length of Stay. Neurol Clin Pract. 2024;14(1):e200218. doi:10.1212/CPJ.0000000000200218. PMID:38173540.